News

<>

April 20, 2017

Scrip

Can Cholesterol Drug Sponsors Make the Case for Statin Intolerance?

By Mary Jo Laffler

Amgen’s FOURIER outcomes study of Repatha supports LDL-lowering in high risk patients, but price may have to come down dramatically to spur wide use of the PCSK9 inhibitors with the subjective condition of statin intolerance.